[Investigation of FOLFIRI/FOLFOX (+/-bevacizumab) therapy for patients with metastatic colorectal cancer in our hospital].

Unlabelled: Bevacizumab has been demonstrated to prolong survival in patients with metastatic colorectal cancer when used in combination with chemotherapy. We investigated the efficacy of chemotherapy administered in our general hospital for patients with metastatic colorectal cancer after the introduction of FOLFOX/FOLFIRI (+/-bevacizumab) therapy.

Subjects And Methods: The subjects in this study were 34 patients diagnosed with metastatic colorectal cancer, who received either FOLFIRI (+/- bevacizumab) or mFOLFOX6 (+/-bevacizumab) therapy in this hospital.

Long-term survival of patients with gallbladder cancer detected during or after laparoscopic cholecystectomy.

Little evidence is available regarding long-term survival of patients with gallbladder cancer that is discovered at the time of laparoscopic cholecystectomy (LC). Therefore the present study was performed to evaluate long-term outcomes of this disease. Of 1546 patients who underwent LC for benign gallbladder disease between January 1992 and January 2002, 8 patients (0.